Gossamer Bio, Inc. (GOSS) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Gossamer Dio Q1 2026 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. To ask a question, simply press star 1 on your telephone keypad. To withdraw your question, press star 1 again. It is now my pleasure to turn the call over to Brian Gerardo, Chief Operating Officer and Chief Financial Officer. Please go ahead. Good morning, and thank you for joining us. Before we begin, I'd like to remind listeners that today's discussion includes forward-looking statements, including statements regarding our regulatory plans, potential NDA submission, and approval timing, commercialization, expectations, cash runway, capital structure, and the potential therapeutic benefit in future developments of Sarah Lutonit. These statements are subject to risks and uncertainties that could cause actual results to differ materially. Please refer to our SEC filings in today's press release for discussions of these risks. We undertake no obligation to update these forward-looking statements except as required by law. We're very excited this morning to have on our call today Fahim Hasning, Karen Peterson, Dr. Rob Resigno. Additionally, we have Dr. Jean-Marie Bruy, Dr. Rainer Zimmerman, Dr. Megan Flynn, Dr. Robin Osterhout, and Bob Smith, our chief commercial officer, to speak about our exciting results this morning. Today, we plan to cover three topics. First, a regulatory update, including our Type B pre-NDA meeting. Secondly, we will discuss results from our ProSERA CT-FRI sub-study. and third, an update on our capital structure, including the co...